免疫检查点抑制剂治疗黑色素瘤患者的疗效
Efficacy of Immune Checkpoint Inhibitors in Treating Patients with Melanoma
摘要: 黑色素瘤是一种起源于黑色素细胞的恶性肿瘤，它是仅次于基底细胞癌和鳞状细胞癌的第三大常见皮肤恶性肿瘤，也是最具侵袭性的皮肤癌，易发生转移而具有较高的致死率。晚期黑色素瘤在历史上一直是一种难以治疗的疾病，因为系统性的治疗方案很少。然而，在过去的几年里，科学的进步导致了新型治疗方法的批准，改变了晚期黑色素瘤的一线管理，其中免疫检查点抑制可以说在黑色素瘤肿瘤学领域和其他领域产生了最大的兴奋。细胞毒性t淋巴细胞相关蛋白4 (CTLA-4)和程序性死亡受体(PD-1)是一种免疫检查点分子，是公认的抗体的靶点，是治疗恶性黑色素瘤的免疫疗法，其功能是控制免疫反应的起始、持续时间和幅度。靶向CTLA-4和PD-1的ICIs已经彻底改变了晚期黑色素瘤和许多其他恶性肿瘤的管理。本文对免疫检查点抑制剂(ICIs)治疗恶性黑色素瘤的疗效进行综述。
Abstract: Melanoma is a malignant tumor that originates from melanocytes. It is the third most common skin malignancy after basal cell carcinoma and squamous cell carcinoma, and is also the most aggressive skin cancer with a high lethality rate due to its tendency to metastasize. Advanced melanoma has historically been a difficult disease to treat because there are few systemic treatment options. However, in the past few years, scientific advances have led to the approval of novel therapeutic ap-proaches that have transformed the first-line management of advanced melanoma, with immune checkpoint inhibition arguably generating the most excitement in the field of melanoma oncology and beyond. Cytotoxic t lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor (PD-1) are immune checkpoint molecules that are recognized targets of antibodies and immuno-therapies for the treatment of malignant melanoma, which function to control the initiation, dura-tion and magnitude of the immune response. ICIs targeting CTLA-4 and PD-1 have revolutionized the management of advanced melanoma and many other malignancies. This article reviews the ef-ficacy of immune checkpoint inhibitors (ICIs) for the treatment of malignant melanoma.
文章引用：马玉婷. 免疫检查点抑制剂治疗黑色素瘤患者的疗效[J]. 临床医学进展, 2023, 13(7): 11691-11698. https://doi.org/10.12677/ACM.2023.1371638

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Schadendorf, D., Van Akkooi, A.C.J., Berking, C., et al. (2018) Melano-ma. The Lancet, 392, 971-984. [Google Scholar] [CrossRef] 
[3] Zaremba, A., Zimmer, L., Griewank, K.G., et al. (2020) Im-munotherapy Beim Malignant Melanoma. Der Internist, 61, 669-675. [Google Scholar] [CrossRef] [PubMed]
[4] Bennet, W.H. (1899) Some Peculiarities in the Behaviour of Certain Malignant and Innocent Growths. The Lancet, 153, 3-7. [Google Scholar] [CrossRef] 
[5] Petrova, V., Arkhypov, I., Weber, R., et al. (2020) Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 21, Article 2367. [Google Scholar] [CrossRef] [PubMed]
[6] Curran, M.A., Montalvo, W., Yagita, H. and Allison, J.P. (2010) PD-1 and CTLA-4 Combination Blockade Expands Infiltrating T Cells and Reduces Regulatory T and Myeloid Cells within B16 Melanoma Tumors. Proceedings of the National Academy of Sciences of the United States of America, 107, 4275-4280. [Google Scholar] [CrossRef] [PubMed]
[7] Goldrath, A.W. and Bevan, M.J. (1999) Selecting and Maintaining a Diverse T-Cell Repertoire. Nature, 402, 255-262. [Google Scholar] [CrossRef] [PubMed]
[8] Fife, B.T. and Bluestone, J.A. (2008) Control of Peripheral T-Cell Tolerance and Autoimmunity via the CTLA-4 and PD-1 Pathways. Immunological Reviews, 224, 166-182. [Google Scholar] [CrossRef] 
[9] Walunas, T.L., Lenschow, D.J., Bakker, C.Y., et al. (1994) CTLA-4 Can Function as a Negative Regulator of T Cell Activation. Immunity, 1, 405-413. [Google Scholar] [CrossRef] 
[10] Krummel, M.F. and Allison, J.P. (1995) CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation. Journal of Experimental Medicine, 182, 459-465. [Google Scholar] [CrossRef] [PubMed]
[11] Brunner, M.C., Chambers, C.A., Chan, F.K., et al. (1999) CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation. The Journal of Immunology, 162, 5813-5820. [Google Scholar] [CrossRef] 
[12] Leach, D.R., Krummel, M.F. and Allison, J.P. (1996) En-hancement of Antitumor Immunity by CTLA-4 Blockade. Science, 271, 1734-1736. [Google Scholar] [CrossRef] [PubMed]
[13] Van Elsas, A., Hurwitz, A.A. and Allison, J.P. (1999) Combi-nation Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) and Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. Journal of Experimental Medicine, 190, 355-366.[CrossRef] [PubMed]
[14] Koga, N., Suzuki, J., Kosuge, H., et al. (2004) Blockade of the Interac-tion between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 2057-2062. [Google Scholar] [CrossRef] 
[15] Hirano, F., Kaneko, K., Tamura, H., et al. (2005) Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. Cancer Research, 6, 1089-1096. [Google Scholar] [CrossRef] [PubMed]
[16] Day, C.L., Kaufmann, D.E., Kiepiela, P., et al. (2006) PD-1 Expression on HIV-Specific T Cells Is Associated with T-Cell Exhaustion and Disease Progression. Nature, 443, 350-354. [Google Scholar] [CrossRef] [PubMed]
[17] Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. [Google Scholar] [CrossRef] [PubMed]
[18] Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., et al. (2005) CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Molecular and Cellular Bi-ology, 25, 9543-9553. [Google Scholar] [CrossRef] 
[19] Krummel, M.F. and Allison, J.P. (1996) CTLA-4 En-gagement Inhibits IL-2 Accumulation and Cell Cycle Progression Upon Activation of Resting T Cells. Journal of Ex-perimental Medicine, 183, 2533-2540. [Google Scholar] [CrossRef] [PubMed]
[20] Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., et al. (1994) CTLA-4 Can Function as a Negative Regulator of T Cell Activation. Immunity, 1, 405-413. [Google Scholar] [CrossRef] 
[21] Alegre, M.L., Noel, P.J., Eisfelder, B.J., Chuang, E., Clark, M.R., Reiner, S.L. and Thompson, C.B. (1996) Regulation of Surface and Intracellular Expression of CTLA4 on Mouse T Cells. The Journal of Immunology, 157, 4762-4770. [Google Scholar] [CrossRef] 
[22] Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T.W., et al. (2000) Immunologic Self-Tolerance Maintained by CD25+CD4+ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-Associated Antigen 4. Journal of Experimental Medicine, 192, 303-310. [Google Scholar] [CrossRef] [PubMed]
[23] Sansom, D.M. (2000) CD28, CTLA-4 and Their Ligands: Who Does What and to Whom? Immunology, 101, 169-177. [Google Scholar] [CrossRef] [PubMed]
[24] Linsley, P.S., Bradshaw, J., Greene, J., Peach, R., Bennett, K.L. and Mittler, R.S. (1996) Intracellular Trafficking of CTLA-4 and Focal Localization towards Sites of TCR Engage-ment. Immunity, 4, 535-543. [Google Scholar] [CrossRef] 
[25] Egen, J.G. and Allison, J.P. (2002) Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength. Immunity, 16, 23-35. [Google Scholar] [CrossRef] 
[26] Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., et al. (2001) Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science, 291, 319-322. [Google Scholar] [CrossRef] [PubMed]
[27] Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E.M., Baker, J., et al. (2011) Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science, 332, 600-603. [Google Scholar] [CrossRef] [PubMed]
[28] Hodi, F.S., O’day, S.J., Mcdermott, D.F., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Mela-noma. The New England Journal of Medicine, 363, 711-723.
[29] Cybulska-Stopa, B., et al. (2020) Efcacy of Ipili-mumab after Anti-PD-1 Therapy in Sequential Treatment of Metastatic Melanoma Patients-Real World Evidence. Ad-vances in Medical Sciences, 65, 316-323. [Google Scholar] [CrossRef] [PubMed]
[30] Shrikant, P., Khoruts, A. and Mescher, M.F. (1999) CTLA-4 Blockade Reverses CD8+T Cell Tolerance to Tumor by a CD4+ T Cell- and IL-2-Dependent Mechanism. Immunity, 11, 483-493. [Google Scholar] [CrossRef] 
[31] Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. The New England Journal of Medicine, 363, 711-723. [Google Scholar] [CrossRef] 
[32] Namikawa, K., Kiyohara, Y., Takenouchi, T., Uhara, H., Uchi, H., Yoshikawa, S., Takatsuka, S., Koga, H., Wada, N., Minami, H., et al. (2018) Efficacy and Safety of Nivolumab in Com-bination with Ipilimumab in Japanese Patients with Advanced Melanoma: An Open-Label, Single-Arm, Multicentre Phase II Study. European Journal of Cancer, 105, 114-126. [Google Scholar] [CrossRef] [PubMed]
[33] McDermott, D., Haanen, J., Chen, T.T., Lorigan, P. and O’Day, S. (2013) Efficacy and Safety of Ipilimumab in Metastatic Melanoma Patients Surviving More than 2 Years Following Treatment in a Phase III Trial (MDX010-20). Annals of Oncology, 24, 2694-2698. [Google Scholar] [CrossRef] [PubMed]
[34] Zou, W. and Chen, L. (2008) Inhibitory B7-Family Molecules in the Tumour Microenvironment. Nature Reviews Immunology, 8, 467-477. [Google Scholar] [CrossRef] [PubMed]
[35] Tsutsumida, A., et al. (2019) Japanese Real-World Study of Sequential Nivolumab and Ipilimumab Treament in Melanoma. The Journal of Dermatology, 46, 947-955. [Google Scholar] [CrossRef] [PubMed]
[36] Fujisawa, Y., et al. (2018) Retrospective Study of Advanced Mela-noma Patients Treated with Ipilimumab after Nivolumab: Analysis of 60 Japanese Patients. Journal of Dermatological Science, 89, 60-66. [Google Scholar] [CrossRef] [PubMed]
[37] Muto, Y., et al. (2019) Investigation of Clinical Factors Asso-ciated with Longer Overall Survival in Advanced Melanoma Patients Treated with Sequential Ipilimumab. The Journal of Dermatology, 46, 498-506. [Google Scholar] [CrossRef] [PubMed]
[38] Baron, K., et al. (2020) Comparative Effectiveness of Second-Line Ipilimumab vs Nivolumab in Combination with Ipilimumab in Patients with Advanced Melanoma Who Received Front-line Anti-PD-1 Antibodies. Journal of Oncology Pharmacy Practice, 27, 555-559. [Google Scholar] [CrossRef] [PubMed]
[39] Mehmi, I. and Hill, J. (2018) Ipilimumab with Anti PD-1 (Nivovlumab or Pembrolizumab) after Progression on First Line Anti-PD-1 Therapy for Advanced Melanoma. Journal of Clinical Oncology, 36, e21552. [Google Scholar] [CrossRef] 
[40] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M. and Wolchok, J.D. (2015) Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 33, 1889-1894. [Google Scholar] [CrossRef] 
[41] Ascierto, P.A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chi-arionSileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) Ipilimumab 10 mg/kg versus Ipilimumab 3 mg/kg in Patients with Unresectable or Metastatic Melanoma: A Randomised, Doubleblind, Multicentre, Phase 3 Trial. The Lancet Oncology, 18, 611-622. [Google Scholar] [CrossRef] 
[42] Institute, N.C. (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
https://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/CTCAE_v5_Quick_Reference _5x7.pdf
[43] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. The New England Journal of Medicine, 372, 320-330. [Google Scholar] [CrossRef] 
[44] Sullivan, R.J., Hamid, O., Gonzalez, R., Infante, J.R., Patel, M.R., Hodi, F.S., Lewis, K.D., Tawbi, H.A., Hernandez, G., Wongchenko, M.J., et al. (2019) Atezolizumab plus Cobimetinib and Vemurafenib in BRAF-Mutated Melanoma Patients. Nature Medicine, 25, 929-935.
[45] Ascierto, P.A., Long, G.V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A.M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., et al. (2019) Survival Outcomes in Patients with Previously Untreated Brafwild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-Up of a Randomized Phase 3 Trial. JAMA Oncology, 5, 187-194. [Google Scholar] [CrossRef] [PubMed]
[46] Michot, J.M., Bigenwald, C., Champiat, S., et al. (2016) Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review. Euro-pean Journal of Cancer, 54, 139-148. [Google Scholar] [CrossRef] [PubMed]
[47] Marrone, K.A., Ying, W. and Naidoo, J. (2016) Immunerelated Adverse Events from Immune Checkpoint Inhibitors. Clinical Pharmacology & Therapeutics, 100, 242-251. [Google Scholar] [CrossRef] [PubMed]
[48] Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) Overall Surviv-al with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 377, 1345-1356. [Google Scholar] [CrossRef] 
[49] Antonia, S.J., Lopez-Martin, J.A., Bendell, J., et al. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895. [Google Scholar] [CrossRef] 
[50] Weber, J.S., Hodi, F.S., Wolchok, J.D., et al. (2017) Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma. Journal of Clinical On-cology, 35, 785-792. [Google Scholar] [CrossRef] 
[51] Larkin, J., Lao, C.D., Urba, W.J., et al. (2015) Efficacy and Safety of Nivolumab in Patients with BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. JAMA Oncology, 1, 433-440. [Google Scholar] [CrossRef] [PubMed]

为你推荐